Your SlideShare is downloading. ×
  • Like
Dabigatran guidelines and reversal PPT
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Dabigatran guidelines and reversal PPT


Dabigatran 2013 PPT

Dabigatran 2013 PPT

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On SlideShare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. DabigatranDr Ihab Suliman2013
  • 2. The New Oral Anticoagulants:Similar Yet Different  Thrombin Inhibitors: 1. Dabigatran: pro-drug, renal clearance - twice daily  FXa Inhibitors: 1. Rivaroxaban: renal clearance - once daily 2. Apixaban: hepatic clearance - twice daily 3. Edoxaban: hepatic clearance - once daily Circulation 2010;121:1523-1532
  • 3. Dabigatran: FDA StatusPradaxa trade nameFor the prevention of DVT/PE after orthopedic surgery: Pradaxa approved in EU and CanadaFor the prevention of stroke in patients with non-valvular atrial fibrillation (SPAF): Pradaxa 150 mg BID FDA approved (Oct. 2010) Pradaxa approved in EU, Canada and Japan
  • 4. Dabigatran: FDA Approved Dosing150 mg BID for SPAF  150 mg for CrCl >30 mL / min  75 mg for CrCl 15-30 mL / min
  • 5. Stroke from Atrial FibrillationAF is the most preventable cause of stroke: 12-16 million will be on warfarin treatment by 2050 in the US Clinical trials have shown stroke can be reduced: Placebo vs ASA = 19% ASA vs warfarin = 30% Placebo vs warfarin = 62% Dabigatran vs warfarin = 34%
  • 6. Dabigatran: Not Without Issues 1. No anticoagulant effect if missed dose • 2% discontinuation rate due to GI distress • Cost of drug ($240/mo vs $4/mo for warfarin) 2. No test to assess anticoagulation 3. Difficult to modulate dose 4. Bleeding in the elderly and renal impaired patients (5 dabigatran related deaths in Japan) 5. ‘Real world’ untested populations 6. Drug interactions 7. Limited data on bridging between anticoagulants 8. No specific antidote 9. 0.2% increase in myocardial infarction 10. Off-label use
  • 7. Dabigatran: Laboratory Testing Monitoring vs anticoagulant assessment  PT and aPTT  Differing reagent sensitivities  Not a linear association between assay values and drug level  Not validated for association to bleeding  aPTT may be applicable for qualitative assessment  INR: not sensitive; not validated  TT: Super-sensitive; can identify if any drug onboard  Ecarin clotting time: results can vary depending on plasma factors; research use only (RUO)  PiCT: RUO  Chromogenic anti-FIIa  Hemoclot: quantitative using dabigatran calibrators; FDA approved yet?